Health IT Analytics February 24, 2021
The five-year study will work to accelerate precision medicine options for patients with non-small cell lung cancer.
In a collaborative study among life sciences companies, oncology providers, and patient advocacy groups, researchers will evaluate up to 12,000 community-based, metastatic non-small cell lung cancer (NSCLC) patients to advance precision medicine treatments.
NSCLC is the most common type of lung cancer, accounting for about 84 percent of lung cancer cases, according to the American Cancer Society.
The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium (MYLUNG) study will observe NSCLC patients over a five-year period in one of the first broad collaborative research efforts in lung cancer.
Specifically, MYLUNG will aim to enhance understanding of molecular testing...
Today's Sponsors
Today's Sponsor